CLINICAL TRIAL: 2MG DOSE OF TH9507, A GROWTH HORMONE RELEASING FACTOR ANALOG IN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 HIV脂肪代谢障碍的特征是内脏脂肪过多、血脂异常和生长激素（GH）水平低下。TH 9507是一种GH释放因子，在生理上增加GH水平。先前的TH 9507研究导致内脏脂肪组织（VAT）和躯干脂肪减少，瘦体重增加和血脂改善，并且通常耐受良好。本研究的目的是评估TH 9507在减少与HIV感染相关的腹部肥胖方面的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV lipodystrophy is characterized by excess visceral fat, dyslipidemia, and low growth hormone (GH) levels. TH9507 is a GH releasing factor that physiologically increases GH levels. A previous study of TH9507 resulted in decreases in visceral adipose tissue (VAT) and trunk fat, increases in lean body mass and lipid profile improvement, and was generally well-tolerated. The purpose of this study is to evaluate the safety and efficacy of TH9507 in reducing abdominal adiposity associated with HIV-infection.